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1. Introduction 
Acute pancreatitis (AP) is a potentially lethal disorder with no specific medical treatment. 
AP is characterized by a spectrum of symptoms, ranging from a local inflammatory process 
to the more severe form (acute necrotizing pancreatitis) which is associated with a systemic 
inflammatory response and a mortality rate of 27-45%. A number of risk factors have been 
identified for AP including alcohol abuse, gallstones, abdominal surgery/injury, cigarette 
smoking, cystic fibrosis, endoscopic retrograde cholangiopancreatography, hypercalcemia, 
hyperparathyroidism, hypertriglyceridemia, infection, pancreatic cancer, and injury to the 
abdomen (Pandol et al., 2007). Alcohol abuse and the development of gallstones account for 
the majority of AP cases. In AP, inappropriate intracellular activation of digestive enzymes 
within the pancreas (e.g. trypsin, chymotrypsin, elastase) is the main initiating event. The 
development of acute necrotizing pancreatitis is usually associated with pancreatic 
glandular necrosis. Acinar cell apoptosis, the release of cytokines, activation of coagulation, 
tissue ischemia, and tissue necrosis are key factors in the progression of the condition, as 
well as in the development of associated extrapancreatic complications (Steinberg & Tenner, 
1994; McKay & Buter, 2003; Pandol et al., 2007).  
AP induces a strong inflammatory response in experimental animal models and in humans, 
and is independent of the initiating factor for acinar cell damage (Granger & Remick, 2005). 
The major inflammatory mediators in AP include tumor necrosis factor (TNF), interleukins 
1, 6, and 8, chemokines, and platelet activation factor (Makhija & Kingsnorth, 2002). Release 
of proinflammatory mediators into the circulation results in a systemic inflammatory 
response syndrome (Granger & Remick, 2005). 
Inflammatory mediators in turn can influence hemostasis. Indeed, the pathways of 
inflammation and coagulation are intimately linked. For example, pro-inflammatory 
cytokines (e.g. TNF, IL-1ǃ) act in autocrine and paracrine loops to activate neutrophils and 
monocytes. These cytokines also activate endothelial cells by upregulating adhesion 
molecules (e.g. P- and E-selectins) and chemokines. This results in leukocyte recruitment to 
the site of injury. Activated monocytes and endothelial cells express tissue factor (TF), the 
“spark” that initiates the coagulation cascade. TF can also be expressed by cells in the 
injured pancreas. The TF/VIIa complex activates factor X to Xa (or factor XI to XIa), and the 
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factor Xa/factor Va complex converts prothrombin to thrombin. Thrombin not only forms 
the fibrin clot but is also a potent activator of protease activated receptor-1 (PAR-1). PAR-1 
activation triggers pro-inflammatory responses including secretion of cytokines and growth 
factors, and upregulation of adhesion molecules.  
In AP, coagulation abnormalities range from localized intravascular thrombosis to 
disseminated intravascular coagulation (DIC). Ultrastructural changes in the pancreas that 
accompany human AP include the infiltration of polymorphonuclear leukocytes into the 
stroma and parenchyma, intra- and extravascular accumulation of platelets, and 
microthrombi in blood vessels (Bockman et al., 1986). This chapter will provide an overview 
of the pathophysiology of acute pancreatitis with emphasis on coagulation abnormalities. 
The topics covered include dysregulation of coagulation and anticoagulant pathways, 
animal studies of AP, and the therapeutic potential of experimental interventions. 
2. Overview of hemostasis 
Hemostasis is a delicate balance between procoagulant (including platelets and clotting 
factors) and anticoagulant mechanisms (including blood flow and the production of 
anticoagulant proteins). It encompasses the vessel wall and endothelial cells, cellular 
constituents within the vessel (such as red blood cells, leukocytes, and platelets), soluble 
plasma proteins (coagulatory proteins and their moderators), as well as microparticles 
derived from leukocytes and platelets (Hoffman & Monroe, III, 2001). It is a physiologic 
process which modulates blood fluidity while also retaining the capacity to produce a 
hemostatic plug outside a damaged blood vessel. Thrombosis is a pathologic event inside 
the vessel lumen, consisting of platelet accumulation, adhesion, activation and aggregation, 
as well as tissue-factor-initiated thrombin generation and fibrin formation (Furie & Furie, 
2007). The hemostatic process is tightly regulated in a healthy individual by a system of 
anticoagulant mechanisms (Dahlback, 2000; Esmon, 2000b; Esmon, 2009). Through these 
mechanisms, the transformation of blood from a liquid to a solid state (and vice versa) is 
tightly regulated by the multiple participants of the coagulation, anticoagulation, and 
fibrinolytic pathways. The following sections describe the key components of the hemostatic 
system and their relevance to AP. Biomarkers of hemostasis in acute human pancreatitis are 
summarized in Table 1. 
3. Platelet activation in AP 
Platelet adhesion at sites of vessel injury is a multistep process involving interactions 
between various platelet receptors and subendothelial adhesive ligands (Furie & Furie, 
2007). The initial tethering of platelets to exposed subendothelial collagen is mediated by 
von Willebrand factor (VWF), a large multimeric protein secreted by endothelial cells and 
activated platelets (Furie & Furie, 2007; Lippi et al., 2009). Adherent platelets become 
activated and undergo a shape change, becoming spherical and extruding long filopodia 
that enhance platelet-platelet interactions. Activated platelets secrete ADP from their dense 
granules and synthesize and release thromboxane A2. Released ADP and thromboxane A2 
bind to distinct receptors on nearby platelets and activate them, thereby recruiting 
additional platelets to the sites of injury. Activated platelets also secrete the contents of their 
alpha granules (e.g. VWF, platelet-derived growth factor, and coagulation cofactors V and 
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VIII) (Wagner & Burger, 2003). Finally, activated platelets promote blood coagulation via the 
expression of phosphatidylserine, a negatively charged phospholipid that is normally found 
on the inside of the platelet cell membrane. Assembly of coagulation factors on the activated 
platelet surface results in an explosive generation of thrombin (described in more detail 
below). 
Evidence of increased platelet activation associated with pancreatitis has long been 
established in experimental animal models. In rabbits, administration of pancreatic fluid 
from patients with chronic pancreatitis induced platelet aggregation and activation (Prinz et 
al., 1984). In cases of acute pancreatitis, platelets have been shown to be activated, and their 
indices (mean platelet volume, platelet large cell ratio, and platelet distribution width) have 
also been shown to be elevated between onset and remission of AP (Mimidis et al., 2004). 
While a heightened platelet response is typical of patients with mild AP, a decreased platelet 
count (due to increased consumption of platelets) is observed in cases of severe AP. Low 
plasma levels of platelets in patients with AP are also associated with poor clinical outcome 
(Maeda et al., 2006). 
4. Coagulation and fibrinolysis abnormalities in AP 
Simultaneous to platelet activation, coagulation occurs in three overlapping stages: 
initiation, amplification, and propagation (Hoffman & Monroe, III, 2001). Tissue factor (TF) 
is the “spark” that initiates blood coagulation. Under normal conditions, TF is not expressed 
by cells that are in direct contact with blood (Butenas & Mann, 2004). After damage to the 
endothelial wall, however, TF is exposed to blood where it is free to bind plasma factor VIIa, 
forming TF-factor VIIa complex. TF is also expressed by macrophages and monocytes after 
stimulation by inflammatory mediators (Esmon, 1999; Nijziel et al., 2001; Bouchard & Tracy, 
2003) 
Tissue factor (TF) forms a complex with a small amount of circulating activated factor VII 
(FVIIa) and acts as a cofactor for increasing the ability of FVIIa to convert FX to FXa and FIX 
to FIXa at the cell surface (Osterud et al., 1978). FXa activates FV and together they convert a 
small amount of prothrombin to thrombin (Monroe et al., 1996). This is known as the 
initiation phase of coagulation. During the amplification phase, the small amount of 
thrombin generated initiates a positive feedback loop upon itself through further activation 
of FV, and thus, increased thrombin generation (Monroe et al., 1996). The initiation of large-
scale thrombin generation begins with the formation of the tenase complex (which consists 
of FVIIIa and FIXa) and the prothrombinase complex (consisting of FVa and FXa) on an 
anionic surface such as activated endothelial cells or platelets (Hoffman & Monroe, III, 
2001). This causes a thrombin burst, which further generates fibrin from fibrinogen. This 
rapid formation of thrombin also activates factor XIII and thrombin-activatable fibrinolysis 
inhibitor (TAFI). Factor XIIIa is then able to cross-link with fibrin strands to support and 
stabilize a fibrin meshwork, while TAFI protects the forming clot from plasmin-mediated 
fibrinolysis (Dahlback, 2000; Butenas & Mann, 2002). 
Plasma levels of TF in AP patients have been shown to be higher than those of healthy 
volunteers, though there is no statistically significant difference in the TF levels between the 
severity groups of AP (Sawa et al., 2006). Plasma levels of TF in alcoholic severe AP with 
pancreatic necrosis was significantly higher than that in alcoholic severe AP without 
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pancreatic necrosis or that in nonalcoholic severe AP with pancreatic necrosis. These 
findings suggest that an increase in plasma TF may be related to the development of 
pancreatic necrosis in alcoholic severe AP.  
Other measurements of blood coagulation are the prothrombin time (PT) and the activated 
partial thromboplastin time (APTT) which measure the extrinsic and intrinsic coagulation 
pathways, respectively. Clinical studies have shown an elevated prothrombin time in 
patients with AP (Radenkovic et al., 2009). However, there have been no reports of 
significant deviations in partial thromboplastin time (APTT) or in F1+2 levels in patients 
with AP. While these measurements suggest early hemostatic disturbances of AP, their 
usefulness in predicting patient outcome is limited. Clinical studies which measure other 
parameters (most notably d-dimer and antithrombin) have demonstrated an improved 
specificity and sensitivity in predicting outcome for these parameters, when compared to 
the utility of either PT or APTT.  
AP is also characterized by abnormalities in fibrinolysis. The fibrinolytic system counteracts 
fibrin deposition, thereby preventing excessive fibrin accumulation at sites of vascular 
injury and restoring blood flow. Plasmin, the enzyme that dissolves fibrin clots, is formed 
from plasminogen in the presence of tissue plasminogen activator (tPA) or urokinase 
plasminogen activator (uPA). Plasmin cleaves fibrin, resulting in the production of fibrin 
degradation products (e.g. D-dimer) (Adams & Bird, 2009).  
The levels of DIC parameters (low levels of platelets and AT, and high levels of D-dimer) 
and thrombin-antithrombin complex upon admission have been found to be associated with 
increased severity and poor prognosis of AP (Maeda et al., 2006). A four-fold increase in D-
dimer levels has been shown to be a marker of complicated AP (Salomone et al., 2003). In 
patients with severe AP, non-survivors have significantly higher levels of D-dimer and 
plasminogen activator inhibitor (PAI)-1 than survivors (Radenkovic et al., 2004). The high 
concentrations of D-dimer and PAI-1 in AP patients are indicative of a hypercoagulable 
state and microvascular coagulopathy which may lead to the formation of microthrombi 
and, ultimately, facilitate the progression of organ failure.  
4.1 Anticoagulant abnormalities in AP 
The potentially explosive nature of the coagulation cascade is tightly regulated by three 
natural anticoagulant systems: antithrombin (AT), the protein C (PC) pathway, and tissue 
factor pathway inhibitor (TFPI).  
4.2 Antithrombin in AP 
AT, a plasma serine protease inhibitor (serpin) synthesized and secreted by the liver, 
demonstrates broad inhibitory activity for enzymes of the coagulation cascade, particularly 
thrombin and factor Xa (Lippi et al., 2009). The rate of enzyme inhibition by AT is slow but 
is accelerated approximately 1000-fold in the presence of negatively charged 
polysaccharides such as pharmacologic heparin as well as heparan sulfate found on the 
endothelial cell surface (Bjork et al., 1992). The stimulatory effect of heparin and heparan 
sulfate is mediated by a unique pentasaccharide sequence which binds AT with high 
affinity. Binding of this pentasaccharide sequence evokes a conformational change in AT 
www.intechopen.com
 
Coagulation Abnormalities in Acute Pancreatitis 
 
63 
that facilitates its interaction with FXa but not with thrombin. To accelerate thrombin 
inhibition by AT, heparin must bind simultaneously to AT and thrombin, a process that 
bridges the enzyme and the inhibitor together in a ternary complex (Bjork et al., 1992). AT 
also demonstrates anti-inflammatory properties through the induction of prostacyclin 
release from endothelial cells, the inhibition of leukocyte-endothelium interactions (e.g. 
rolling and adhesion), the inhibition of procoagulant cellular signaling pathways, and the 
alteration of cellular receptor expression which modulate lysosomal proteinases, interleukin 
release, and soluble intercellular adhesion molecules (Mammen, 1998; Esmon, 2005). 
In patients with AP, low levels of AT (< 69%) at admission were found to be associated with 
a poor prognosis (Maeda et al., 2006). In taurocholate-induced experimental pancreatitis in 
rats, high dose AT treatment was shown to improve survival (Bleeker et al, 1992). In 
cerulein-induced AP, AT supplementation inhibited the release of high mobility group box 1 
protein (HMGB1) as well as other proinflammatory cytokines in rats (Hagiwara et al., 2009). 
However, in a systematic review of randomized trials, AT  seems ineffective in improving 
overall mortality in critically ill patients (Afshari et al., 2007). 
4.3 The protein C pathway in AP 
The second natural anticoagulant is PC, a vitamin-K dependent glycoprotein synthesized by 
the liver. The PC pathway provides an “on site” and “on demand” anticoagulant response 
whenever thrombin is generated (Esmon, 2000c; Esmon, 2000a). Briefly, vascular injury 
initiates the coagulation cascade, ultimately resulting in thrombin generation and blood clot 
formation. Excess thrombin then binds to thrombomodulin (TM), a receptor found on the 
surface of vascular endothelial cells. The binding of thrombin to TM is critical for efficient 
protein C activation because this interaction induces a major specificity change in thrombin 
that increases its rate of protein C cleavage (ie. activation) by 1000-fold. The conversion of 
PC to APC is augmented approximately 20-fold in vivo by the endothelial cell protein C 
receptor (EPCR). EPCR binds circulating protein C and presents it to the thrombin-TM 
complex. Activated protein C (APC), in conjunction with its cofactor protein S (PS), 
degrades coagulation cofactors Va and VIIIa on the surface of negatively-charged 
phospholipids (e.g. activated platelets).  
Significant changes in protein C levels were observed in both experimental and clinical AP. 
In rabbits, a rapid decrease in PC levels was found after the induction of acute necrotizing 
pancreatitis (Ottesen et al., 1999). Serial measurements of PC in AP patients have shown a 
difference between surviving and non-surviving patients. Survivors exhibited a progressive 
normalization of PC levels in plasma, while patients who died exhibited no increase in PC 
levels (Radenkovic et al., 2004). Decreased PC levels may reflect an increased consumption 
of PC, vascular leakage, or impaired PC synthesis by the liver in the diseased state (Levi & 
ten Cate, 1999). Upregulated but insufficient generation of APC was shown to be associated 
with the development of multiorgan failure in severe AP (Lindstrom et al., 2006).  
Plasma levels of soluble TM (important for PC activation) increase throughout the course of 
AP (Ida et al., 2009). Soluble TM levels were also significantly higher in non-surviving 
patient subgroups when compared with survivors. Exhibiting a specificity of 91% in 
predicting the prognosis of AP, sTM levels may be a useful prognostic marker for early 
mortality predictions. 
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4.4 Tissue Factor Pathway Inhibitor (TFPI) in AP 
The third natural anticoagulant is tissue factor pathway inhibitor (TFPI), a Kunitz-type 
serine protease inhibitor that is produced by monocytes, macrophages, the liver, as well as 
endothelial cells (Lwaleed & Bass, 2006). It is stored mainly in three different regions of the 
body: in circulation, in the cytoplasm of platelets, and bound to the endothelium 
(DelGiudice & White, 2009). TFPI forms a quaternary complex with TF, factor FVIIa, and 
factor Xa, thereby preventing further production of factor Xa and factor IXa by the TF:VIIa 
complex and blocking additional generation of thrombin by factor Xa. 
Yasuda et al. examined the levels of TFPI in patients with AP (Yasuda et al., 2009). Plasma 
TFPI levels in patients with AP were significantly higher than those in healthy volunteers, 
and plasma TFPI levels in severe AP were greater than those in mild AP. The elevation of 
TFPI appeared to be positively correlated with the severity, degree of necrosis, as well as 
incidence of organ dysfunction. 
5. Therapeutic strategies in AP 
Modulation of hemostasis may be an attractive strategy to treat AP. Experimental animal 
models include administration of activated protein C (APC) to improve microvascular 
coagulation and inflammation. Other strategies target procoagulant factors such as platelet 
activating factor (PAF), platelets, and factor VIIa.  
5.1 Activated protein C in AP 
Recombinant human APC (rAPC; Drotrecogin alpha activated; Xigris®) is the first biological 
agent to improve survival in patients with severe sepsis , a common co-morbidity associated 
with AP (Bernard et al., 2001; Bernard et al., 2004). Studies investigating the protective 
properties associated with APC treatment in vivo and in vitro have shown that APC 
functions not only as an anticoagulant, but also as a cytoprotective signaling molecule 
involved in inflammation, apoptosis, and vascular permeability. The protective effect of 
rAPC therapy in patients with severe sepsis likely reflects its ability to modulate the 
complex changes associated with sepsis pathophysiology. 
The importance of the protein C anticoagulant pathway in AP was first studied in a rabbit 
model. Induction of severe AP caused a marked decrease in protein C activity compared to 
rabbits subjected to sham surgery (Ottesen et al., 1999), an effect that is also observed in non-
surviving patients with AP. More recently, Chen et al. elucidated the effects of APC 
treatment on coagulation mechanisms in AP. In a 5% retrograde sodium taurocholate 
infusion rat model, pretreatment with 50 ug/kg of APC versus untreated rats with AP 
resulted in significant decreases in serum TNF, serum IL-8, and pancreatic matrix 
metalloproteinase 9 (MMP-9), an enzyme which degrades a wide range of extracellular 
matrix components (e.g. collagen, fibronectin, and gelatin). Moreover, APC-treated rats had 
significantly higher levels of pancreatic EPCR and TM, receptors critical for protein C 
activation. It has been shown that endotoxins increase shedding of membrane EPCR to 
produce soluble EPCR via MMP-9 (Gu et al., 2000) which respond to an increase in 
inflammatory cytokines (Wright & Friedland, 2004). It is proposed that APC treatment 
downregulates MMP-9 expression, thus reducing the shedding of EPCR to enhance 
endothelial EPCR cell expression in the pancreas. Following this study, the therapeutic 
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effects of rAPC in AP have been demonstrated in various models of AP by different groups 
(Yamanel et al., 2005; Alsfasser et al., 2006; Chen et al., 2007) while others have shown no 
survival benefit attributed to treatment with APC (Akay et al., 2008). 
The anti-inflammatory and protective functions of APC have been documented in severity-
graded models of AP. In a 5% sodium taurocholate infusion model (via the common 
biliopancreatic duct) of acute necrotizing pancreatitis, it was found that treatment with 
recombinant human APC (bolus injection of 100 µg/kg) 6 hours following AP induction was 
associated with a decrease in pancreatic bacterial contamination as well as fewer mesenteric 
lymph nodes (Yamanel et al., 2005). APC-treated animals with AP also had significantly 
decreased amylase levels, plasma IL-6, and TNF-ǂ by decreasing NF-ĸǃ activation. 
Moreover, APC treatment resulted in improvements in pancreatic histology as reflected by 
the resolution of pancreatic edema, perivascular inflammation, acinar cell necrosis, and fat 
necrosis. This study found that APC neither worsened nor improved the hemorrhagic state 
of the pancreas in the experimental condition suggesting that the coagulation system 
remains intact despite significant pancreatic tissue injury in the early pathophysiology of 
acute necrotizing pancreatitis (Yamanel et al., 2005). 
In a rat model of mild (cerulein injection) and severe AP (intravenous cerulein injection with 
intraductal glycodeoxycholic acid infusion), treatment with recombinant human APC  at 100 
ug/kg per hour for 6 hours significantly reduced inflammation in the lungs and pancreas 
and furthermore improved survival from 38%-86% (p = 0.05) (Alsfasser et al., 2006). 
Inflammation was characterized by the presence of myeloperoxidase (MPO) in the pancreas 
and lungs of rats with severe AP, which decreased significantly with APC treatment for 6 
hours following induction of AP. MPO levels in the lungs were reduced to levels even lower 
than those in sham-operated rats, similar to levels observed in healthy mice, while MPO 
levels in the pancreas were reduced to those observed in sham-operated and healthy control 
animals, demonstrating the anti-inflammatory effect of APC (Alsfasser et al., 2006). In 
contrast, no significant changes in coagulopathy were observed in untreated rats with severe 
AP versus APC-treated rats. Coagulopathy associated with severe AP was characterized by 
significantly prolonged prothrombin and partial thromboplastin times, decreased 
fibrinogen, marked leukocytosis, and thrombocytopenia, which were not significant in 
untreated versus APC-treated rats. APC appears to offer a survival benefit by suppressing 
inflammation in the pancreas and lungs without concomitant reversal of the pancreatic 
tissue damage and coagulopathy observed in experimental severe AP (Satake et al., 1981; 
Alsfasser et al., 2006).  
Further studies aimed at elucidating the mechanism by which APC treatment improves 
outcome in AP demonstrated the involvement of mitogen-activated protein kinases 
(MAPKs) (Chen et al., 2007). MAPKs are mammalian serine/threonine protein kinases 
known to amplify signals involved in differentiation, inflammation, and apoptosis 
(Robinson & Cobb, 1997). P38 MAPK and JNK/SAPK (c-Jun N-terminal kinase/stress-
activated protein kinase) are stress-responding MAPKs which induce inflammatory 
pathways in the early pathogenesis of severe AP (Dabrowski et al., 2000; Samuel et al., 2003). 
In this study, severe AP was induced through retrograde infusion of a 5% sodium 
taurocholate solution via the pancreatic duct at 100 uL/min. Rats were pretreated before AP 
induction with a 50 ug/kg dose of APC, 10 ug/kg dose of APC, or CNI1493 (a synthetic 
molecule which significantly reduces AP severity by inhibiting MAPK phosphorylation thus 
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attenuating inflammatory pathways (Lowenberg et al., 2004; Denham et al., 2000). In rats 
with severe AP, p38 MAPK and JNK2 proteins as well as inflammatory mediators TNF and 
IL-1ǃ were significantly elevated. These effects were reversed in rats treated with the higher 
APC dose and CNI1493 (Chen et al., 2007). Decreases in the protein expression of MAPKs 
and cytokines in both treatments were comparable to levels in the healthy control group 
(Lowenberg et al., 2004; Wang et al., 2005; Chen et al., 2007). Moreover, APC treatment at 50 
ug/kg and not CNI1493 significantly increased expression of ERK1/2 protein (Chen et al., 
2007), the activation of which is known to protect against cell injury by promoting cellular 
regeneration (Sapieha et al., 2006). 
These studies demonstrated that APC at a dose of 50 ug/kg inhibits p36 MAPK and JNK 
expression, thus reducing levels of proinflammatory cytokines like TNF and IL-1ǃ in the 
pancreas. Additional protective effects of APC include the upregulation of ERK1/2 which 
promotes pancreatic cell regeneration and diminishes the severity of AP. 
While some studies demonstrated the therapeutic potential of APC with high bolus APC 
injections (Yamanel et al., 2005; Chen et al., 2007) and hourly infusion (Alsfasser et al., 2006) 
treatments, others have suggested that APC offers no survival benefit in early phase AP 
(Akay et al., 2008). In a 5% sodium taurocholate rat AP model, APC was given hourly at the 
same dose given in the PROWESS study which tested the therapeutic effects of APC in 
sepsis patients (Bernard et al., 2001). Akay et al. found that APC treatment at 24 ug/kg per 
hour given 4 hours after AP induction resulted in significantly reduced serum IL-6 and 
amylase levels compared to untreated rats with AP (Akay et al., 2008). However, no 
significant improvements in pancreatic histology, pancreas oxidative stress, pancreas MPO, 
or renal function were observed. It is possible that that differences observed regarding the 
therapeutic benefit of APC may be due to dosage effects and differences in experimental 
design. The use of a lower dose of APC (24 ug/kg) may have been insufficient to offer any 
therapeutic benefit compared to the previous studies using 100 ug/kg of APC bolus or 
hourly (Yamanel et al, 2005; Alsfasser et al, 2006). Furthermore, the PROWESS trials used 
the 24 ug/kg per hour dose over 96 hours versus 5 hours in the experimental AP study 
(Akay et al., 2008). As such, studies testing the therapeutic effects of APC treatment in 
animal models of AP have yielded varying results. 
5.2 Targeting Platelet Activating Factor (PAF) and platelets in AP 
Modulation of platelet activating factor (PAF) has also been studied in experimental AP. 
PAF is a receptor-binding lipid and vasodilator that activates basophils, endothelial cells, 
platelets, and neutrophils. It is the most extensively studied experimental therapy in clinical 
trials of AP. In sodium taurodeoxycholate and trypsin injection models (via the 
biliopancreatic duct), PAF is released into the peritoneal fluid, bloodstream, and lung of rats 
(Kald et al., 1993). Furthermore, inhibition of PAF via an antagonist or an enzyme 
accelerating its degradation (acetylhydrolase) decreased inflammation characterized by 
marked reductions in pro-inflammatory cytokines (Lane et al., 2001; Hofbauer et al., 1998), 
pancreatic enzyme activation (Fujimura et al., 1992), and improved survival (Leonhardt et 
al., 1992; Dabrowski et al., 1995), hemodynamics (Ais et al., 1992), and histology (Dabrowski 
et al., 1995) in caerulein- (Fujimura et al., 1992; Lane et al., 2001; Hofbauer et al., 1998), 
deoxycholate- (Ais et al., 1992), taurocholate-infusion (Leonhardt et al., 1992; Dabrowski et 
al., 1995) and murine bile duct ligation models (Hofbauer et al., 1998). 
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The therapeutic effects of reducing pro-inflammatory platelet activity while maintaining its 
hemostatic abilities have also been studied. The inflammatory role of platelets was 
demonstrated in a study where platelet supernatant administered to platelet-depleted mice 
restored normal leukocyte recruitment (Tamagawa-Mineoka et al., 2007). In a cerulein 
model of AP, platelet depletion via an antibody (anti-GP1bǂ) reduced many markers of 
severe AP including serum amylase levels, acinar cell necrosis, interstitial pancreatic 
hemorrhage, inflammatory infiltration by neutrophils, pancreatic MPO, pancreatic 
macrophage inflammatory protein-2 (MIP-2), and circulating leukocytes and neutrophils 
(Abdulla et al., 2011a). This study along with others showed that platelets exert a pro-
inflammatory response by invoking MIP-2 chemokine synthesis in pancreatic cells 
(macrophage and acinar cells) (Ramnath & Bhatia, 2006; Sun & Bhatia, 2007), a major signal 
for neutrophil infiltration and chemotaxis (Bhatia & Hegde, 2007; Li et al., 2004). Therefore 
targeting the inflammatory nature of platelets may have therapeutic potential in reducing 
pancreatic tissue injury and the severity of acute pancreatitis (Abdulla et al., 2011). 
Measurement Biomarker Effect Normal 
Value
AP Admission 
Value
References 
Global 
Coagulation 
PT (sec.) Increased 9.8-12.7 13.46-13.92 1,2 
APTT (sec.) NS† 21-39 32.99-33.22 1,2,3,4,5 
Platelet Count 
(10΀/µl) NS† 9.2 Sur-vivor Non-Survivor 1,6 
16.2 6.8
Fibrinogen (g/L) Increased 1.8-3.5 3.7-5.39 1,2 
Procoagulant 
Activity 
D-dimer (ng/mL) Increased 0-0.39 5.5-903.50 1,3,4,7,8 
TAT (µg/L) Increased 1-16.1 11.8-25.3 3,4,6 
TF antigen 
(pg/ml)
Increased 120-140 363-721 7,9,10 
sP-selectin 
(ng/mL)
Increased 82-181 150-215 11,12,13 
Fibrinolysis 
Pathway 
Alpha-2-
Antiplasmin (%)
Decreased 80-120 73.22-105.28 1,2 
PAI-1 (U/mL) Increased 0.3-3.5 4.39-4.56 1,2,4 
Plasminogen 
(µg/mL)
Decreased 150 - 200 70.11-103.94 1,2,17 
Anticoagulant 
Activity 
AT (%) Decreased 80-120 63.47- 81.47 1,2,4,5 
PC (%) Decreased 81-173 52-84.75 1,2,4,5,8 
APC (%) Decreased 100% 76-102 2 
Protein S 
(µg/mL)
Decreased 23.8-30.6 17.3-26.9 16 
sTM (ng/mL) Increased 10.3-54 23.48-153.9 4,14,18 
TFPI (ng/mL) Increased 26.4-28.6 34.6-40.4 15 
¹Radenkovic et al. 2009; ²Radenkovic et al. 2004; ³Mavrommatis et al. 2000; ΀Kinasewitz et al. 2004; ΁Collins et al. 2006; ΂Maeda et al. 2006; ΃Stief et al. 2007; ΄Lindstrom et al. 2006; ΅Sawa et al. 2006; ¹⁰Gando 
et al. 1998; ¹¹Powell et al. 2001; ¹²Ogura et al. 2001; ¹³Osmanovic et al. 2000; ¹΀Lu et al. 2007; ¹΁Yasuda et al. 
2009; ¹΂Uehara et al. 2009; ¹΃Vinazzer et al. 1988; ¹΄Ida et al. 2009;  
†Denotes a non-significant value compared with normal controls. 
Table 1. Biomarkers of hemostasis in human acute pancreatitis. 
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5.3 Inhibition of factor VIIa in AP 
The effect of inhibiting FVIIa on experimental AP was investigated in an intraductal 
taurodeoxycholate infusion model of AP (Andersson et al., 2007). Administration of active-
site inactivated FVII (FVIIai) and N-acetylcysteine (NAC, an anti-inflammatory antioxidant) 
90 minutes prior to AP induction caused a significant reduction of MPO levels in distant 
organs like the lungs and ileum and reductions in plasma IL-6 and MIP-2 compared to 
saline controls 6 hours following AP induction (Andersson et al., 2007). This study suggests 
that coagulant mediators may potentially be therapeutic targets to decrease AP severity. 
6. Conclusions 
Coagulation abnormalities are a hallmark of AP and are related to disease severity. Results 
from experimental animal studies and human studies suggest that modulation of 
hemostasis may provide a therapeutic target for the treatment of AP. Inhibition of the 
coagulation cascade may prevent intravascular coagulation and inflammation in the 
pancreas and distant organs, thereby reducing systemic complications in patients with acute 
pancreatitis. 
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